The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non–small cell lung cancer (NSCLC): KEYNOTE-867.

Salma K.  Jabbour

Consulting or Advisory Role - IMX Medical Reviewer; Merck Sharp & Dohme; Syntactx

Research Funding - Merck Sharp & Dohme (Inst); NCI (Inst)

Baerin  Houghton

Consulting or Advisory Role - AstraZeneca; Merck

Research Funding - Merck Sharp & Dohme (Inst)

Andrew George  Robinson

Honoraria - Merck

Consulting or Advisory Role - Amgen; AstraZeneca; Merck

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Roche Canada (Inst)

Xavier  Quantin

Honoraria - Amgen; AstraZeneca; AstraZeneca; BMS France

Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Boehringer Ingelheim; MSD Oncology; MSD Oncology; Pfizer

Thomas  Wehler

Research Funding - Merck Sharp & Dohme (Inst)

Dariusz  Kowalski

Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Serono; MSD; Roche/Genentech

Research Funding - Merck Sharp & Dohme (Inst)

Myung-Ju  Ahn

Honoraria - Amgen; AstraZeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN

Consulting or Advisory Role - Alpha pharmaceutical; Amgen; AstraZeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN

Research Funding - YUHAN

Mustafa  Erman

Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Nobelpharma

Consulting or Advisory Role - MSD; Nobelpharma; Roche; Takeda

Research Funding - Merck Sharp & Dohme (Inst)

Giuseppe  Giaccone

Consulting or Advisory Role - Daiichi; Eisai; Janssen Oncology; Novartis; Radiomics; Sanofi; Sanofi/Regeneron; Spectrum Pharmaceuticals

Research Funding - Cantargia AB (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst)

Hossein  Borghaei

Stock and Other Ownership Interests  - Nucleai; Rgenix; Sonnet

Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Pfizer

Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Beigene; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; EMD Serono; Genentech; Genmab; Guardant Health; HUYA Bioscience International; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; PharmaMar; Regeneron; Rgenix; Sonnet; Takeda

Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)

Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly; Merck; Novartis

Other Relationship - Incyte; Takeda; University of Pennsylvania

Jessica  McLean

Employment - Merck Sharp & Dohme

Yan  Xu

Employment - Merck Sharp & Dohme

Fabricio  Souza

Employment - Merck Sharp & Dohme

Stock and Other Ownership Interests  - Merck

Georg  Pall

Research Funding - Merck Sharp & Dohme (Inst)